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ABSTRACT: Eslicarbazepine acetate (BIA 2-093) is a novel central nervous system drug undergoing clinical phase III trials for
epilepsy and phase II trials for bipolar disorder. A simple and reliable chiral reversed-phase HPLC-UV method was developed
and validated for the simultaneous determination of eslicarbazepine acetate, oxcarbazepine, S-licarbazepine and R-licarbazepine
in human plasma. The analytes and internal standard were extracted from plasma by a solid-phase extraction using Waters Oasis®
HLB cartridges. Chromatographic separation was achieved by isocratic elution with water–methanol (88:12, v/v), at a flow rate
of 0.7 mL/min, on a LichroCART 250-4 ChiraDex (β-cyclodextrin, 5 μm) column at 30°C. All compounds were detected at
225 nm. Calibration curves were linear over the range 0.4–8 μg/mL for eslicarbazepine acetate and oxcarbazepine, and 0.4 – 80 μg/
mL for each licarbazepine enantiomer. The overall intra- and interday precision and accuracy did not exceed 15%. Mean relative
recoveries varied from 94.00 to 102.23% and the limit of quantification of the assay was 0.4 μg/mL for all compounds.
This method seems to be a useful tool for clinical research and therapeutic drug monitoring of eslicarbazepine acetate and its
metabolites S-licarbazepine, R-licarbazepine and oxcarbazepine. Copyright © 2007 John Wiley & Sons, Ltd.
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INTRODUCTION
Until the last decade of the twentieth century, epileptic
seizures were still managed by antiepileptic drugs
(AEDs) such as carbamazepine (CBZ), phenytoin,
valproic acid, ethosuximide, phenobarbital and some
benzodiazepines (Levert et al., 2002). However, since
the beginning of the 1990s, an explosion in knowledge
about the neurobiology of epileptogenesis has taken
place and several new AEDs have been introduced in
clinical practice, such as vigabatrin, zonisamide, lamo-
trigine, gabapentin, felbamate, topiramate, tiagabine,
oxcarbazepine (OXC) and levetiracetam (Bazil and
Pedley, 1998; Ducan, 2002). Despite the currently avail-
able therapeutic arsenal of old and new AEDs, about
30% of epileptic patients are still not seizure-free, and
therefore, there is a substantial need to develop more
effective drugs simultaneously with less potential for
drug interactions and side effects (Deckers et al., 2003;
Bialer, 2006).
Eslicarbazepine acetate (ESL) [S-(−)-10-acetoxy-10,11-
dihydro-5H-dibenz/b,f/azepine-5-carboxamide], previously
known as BIA 2-093, is a novel chiral drug presently
completing phase III clinical trials, as add-on therapy
in refractory partial epilepsy, and undergoing phase II
clinical trials, as monotherapy in partial epilepsy and in
bipolar disorder (Almeida and Soares-da-Silva, 2007).
ESL is chemically related to CBZ and OXC (Benes
et al., 1999). CBZ is a very effective first-generation AED
that is used as a major first-line drug for partial and
generalized tonic–clonic seizures (Arroyo and Kramer,
2001; Coppola, 2004). In humans, the major metabolic
pathway of CBZ is oxidation to carbamazepine-10,11-
epoxide, which seems to be responsible for several
unwanted adverse effects and CBZ-related drug in-
teractions resulting from the induction of hepatic
microssomal cytochrome P450 enzymes (Myllynen
et al., 1998; Arroyo and Kramer, 2001; Coppola, 2004).
OXC is a second-generation CBZ, presenting a similar
spectrum of anticonvulsant activity but showing a more
favourable tolerability profile (Reinikainen et al., 1987;
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Schachter, 1999). Chemically, OXC differs from CBZ
by a keto-group in the tenth position. Therefore, in
humans, the achiral prodrug OXC is rapidly reduced
in liver by cytosolic arylketone reductases to the
pharmacologically active metabolite licarbazepine or
10-hydroxy-carbazepine (May et al., 2003; Flesch, 2004).
Nevertheless, OXC first-pass reduction to licarbazepine
is stereoselective, appearing in plasma as S-
licarbazepine (S-LC) and R-licarbazepine (R-LC) in the
enantiomeric ratio of approximately 4:1 (Flesch et al.,
1992; Volosov et al., 1999). In fact, it is well known that
enantiomers of chiral drugs may have different phar-
macodynamic, pharmacokinetic and toxicological effects
in biological systems (Misl’anová and Hutta, 2003).
Accordingly, the enantiomeric dilution of the active
metabolite of OXC is a negative aspect and the develop-
ment of a single enantiomer (eutomer) or the mani-
pulation of the enantiomeric ratio could be performed
in order to optimize the therapeutic index. Thus, ESL,
a third-generation CBZ or second-generation OXC, was
specifically designed to circumvent its further biotrans-
formation to toxic metabolites, such as epoxides, and to
avoid enantiomeric impurity and unnecessary produc-
tion of enantiomers or diastereoisomers of its meta-
bolites, without losing anticonvulsant potency (Benes
et al., 1999; Hainzl et al., 2001). As a result, ESL exhibits
a ‘cleaner’ metabolism and higher enantiomeric purity
than OXC (Hainzl et al., 2001). Previous reports in-
dicated that ESL is extensively metabolized to S-LC
(95–98%) and to a minor extent to R-LC and OXC
(Almeida and Soares-da-Silva 2004; Almeida et al., 2005).
Over the years, several chromatographic methods for
OXC and racemic licarbazepine determination have
been developed (Noirfalise and Collinge, 1983; Menge
et al., 1987; Elyas et al., 1990; Rouan et al., 1994;
Pienimaki et al., 1995; Souppart et al., 2001; Levert
et al., 2002; Mandrioli et al., 2003; Franceschi and
Furlanut, 2005; Lanckmans et al., 2006). However, only
three chiral HPLC assays have been validated to deter-
mine S- and R-LC enantiomers, in which a very expen-
sive column and mobile phase were employed (Flesch
et al., 1992; Pichini et al., 1995; Volosov et al., 2000).
ESL and its metabolites S-LC, R-LC and OXC have
also been previously evaluated by a chiral HPLC-MS
method, but it was not completely described (Hainzl
et al., 2001; Almeida et al., 2005).
As ESL is a new drug in final phase of clinical trials,
in our opinion it would be essential to develop and
validate a simple chiral HPLC-UV method for simulta-
neous and stereoselective determination of ESL and
its main metabolites in human plasma. Moreover, con-
sidering that epilepsy is a neurological disease with high
prevalence and high incidence in patients younger than
1 year and older than 75 years (Arroyo and Kramer,
2001; Jarrar and Buchhalter, 2003), the availability of
an easy-to-use HPLC-UV method is also imperative to
achieve individualized dosage regimens and to improve
the overall clinical outcomes by monitoring plasma drug
concentrations in these special populations (Perucca,
2000; Johannessen et al., 2003; Neels et al., 2004).
The purpose of this paper is to describe an accurate,
sensitive and practical enantioselective HPLC-UV
assay to quantify ESL and its metabolites in human
plasma, within a wide concentration range, which could
be applied not only to clinical research but also to
therapeutic drug monitoring.
EXPERIMENTAL
Chemicals and reagents. Standards of ESL (BIA 2-093, lot
number 0000012976, 100% pure by HPLC), S-LC (BIA
2-194, lot number PC020131B, 99.79% pure by HPLC), R-LC
(BIA 2-195, lot number PC040414, 100% pure by HPLC),
OXC (lot number 97.12.17, >98% pure by HPLC) and BIA
2-265 (used as internal standard, lot number PC050704,
97.4% pure by HPLC) were kindly supplied by BIAL (Porto,
Portugal; Fig. 1). Methanol (HPLC grade, SDS), water milli-
Q (HPLC grade, >15 MΩ, home-made), acetonitrile, ethyl
acetate, sodium dihydrogen phosphate dihydrate, di-sodium
hydrogen phosphate dehydrate and hydrochloric acid fuming
37% were purchased from Merck KGaA (Darmstadt,
Germany). Drug-free human plasma from healthy donors
was kindly provided by the Portuguese Blood Institute after
the written consent of each subject.
Chromatographic apparatus and conditions
The HPLC system used for analysis was composed of a BAS-
480 liquid chromatograph equipped with a PM-80 pump,
a Rheodyne manual injector with a 20 μL loop, a BAS UV-
116 UV–vis detector, a BAS LC-22C temperature controller,
a BAS DA-5 chromatography control and a data system
interface (all from Bioanalytical Systems, West Lafayette, IN,
USA). Data collection and integration were achieved by
means of BAS Chromgraph Control and Chromgraph Report
software version 2.30.
The chromatographic separation of all four drugs and
internal standard was carried out at 30°C by isocratic elution
with water–methanol (88:12, v/v), at a flow rate of 0.7 mL/
min, on a LiChroCART 250-4 ChiraDex (β-cyclodextrin,
5 μm) column protected by a LiChroCART 4-4 ChiraDex
(β-cyclodextrin, 5 μm) guard column purchased from Merck
KGaA (Darmstadt, Germany). The mobile phase was filtered
through a 0.45 μm filter and degassed ultrasonically for
15 min before use. A sample volume of 20 μL was injected
and the analytes were detected at 225 nm.
Stock solutions, calibration standards and quality
control samples
The stock solutions of ESL (2 mg/mL), S-LC (10 mg/mL),
R-LC (10 mg/mL), OXC (2 mg/mL) and internal standard
(1 mg/mL) were prepared by dissolving appropriate amounts
of each compound in acetonitrile. These solutions were
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Figure 1. Chemical structures of eslicarbazepine acetate (ESL), S-licarbazepine
(S-LC), R-licarbazepine (R-LC), oxcarbazepine (OXC) and BIA 2-265 used as
internal standard (IS).
adequately diluted with acetonitrile in order to give S-LC
and R-LC 2 mg/mL solutions and ESL, S-LC, R-LC and
OXC 200 μg/mL solutions. The stock and working solutions
were used appropriately to afford five combined spiking solu-
tions of all four drugs with final concentrations of 10, 50, 500,
1000 and 2000 μg/mL for S-LC and R-LC and 10, 20, 50, 100
and 200 μg/mL for ESL and OXC. An internal standard
working solution of 200 μg/mL was prepared by diluting
appropriately the respective stock solution. All standard solu-
tions were stored at approximately 4°C and protected from
light for one month, except the internal standard working
solution, which was prepared daily.
Calibration standards at 0.4, 0.8, 2, 4 and 8 μg/mL for ESL
and OXC and at 0.4, 2, 20, 40 and 80 μg/mL for S-LC and
R-LC were prepared by adding known amounts of the appro-
priate combined spiking solutions to blank human plasma.
Quality control (QC) samples were prepared independently
in the same matrix (blank human plasma).
Extraction procedure
Aliquots of human plasma (250 μL) were added to 750 μL
of 0.1 M sodium phosphate buffer (pH 5) spiked with 10 μL
of the internal standard working solution. The samples were
vortex-mixed and loaded into Oasis® HLB (30 mg, 1 mL)
cartridges (Waters, Milford, MA, USA), which were previ-
ously conditioned with 1 mL of methanol, 1 mL of acetonitrile
and 1 mL of water–acetonitrile (95:5, v/v). After sample
elution, the loaded cartridges were submitted to −30 kPa and
washed twice with 1 mL of water and twice with 1 mL of
water–acetonitrile (95:5, v/v). After drying the sorbent under
airflow for 5 min, the analytes were eluted with 1 mL of ethyl
acetate under gentle vacuum and then the cartridges were
dried for 30 s at −30 kPa. The eluates were evaporated to
dryness under a nitrogen stream at 45°C and the residues
reconstituted in 100 μL of HPLC mobile phase, vortexed for
approximately 30 s and placed in an ultrasonic bath at room
temperature for approximately 1 min. Following this, the
reconstituted extracts were transferred to 0.22 μm Spin-X
centrifugal filters, centrifuged at 13,400 rpm for 2 min and
20 μL of the final filtered samples were injected onto the
HPLC system.
Method validation
The method was validated according to the general recom-
mendations published in the last few years concerning to
bioanalytical method validation and acceptance criteria for
validation parameters: selectivity, linearity, sensitivity, preci-
sion, accuracy, sample dilution, recovery and stability (Shah
et al., 2000; Peters and Maurer, 2002).
Method selectivity. The extracts of blank human plasma
samples from six different subjects were tested for endo-
genous interferences. Furthermore, solutions of several com-
monly co-prescribed AEDs such as phenobarbital, phenytoin,
carbamazepine, valproic acid, felbamate, gabapentin, vigaba-
trin, lamotrigine, topiramate and levetiracetam, and solutions
of non-AED cotherapies including antidepressants (dothiepin,
mirtazapine, sertraline, trazodone, escitalopram and paroxe-
tine), anxiolytics or hypnotics (diazepam, cloxazolam, loraze-
pam and ethyl loflazepate) and antipsychotics (risperidone,
olanzapine, chlorpromazine and zuclopenthixol) were also in-
jected to check for drugs which could potentially interfere
with eslicarbazepine acetate and its metabolites.
Calibration curve. The linearity of the analytical method
was assessed by using calibration standards at five different
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concentrations within the range of 0.4–8 μg/mL for ESL and
OXC and 0.4–80 μg/mL for R-LC and S-LC. Calibration
curves were constructed by plotting drug–internal standard
peak height ratio as a function of the respective concentra-
tions in the calibration samples. The data were subjected to
a weighted linear regression analysis using 1/x2 as weighting
factor, which was chosen taking the plots and the sums of
absolute percentage relative error into account (Almeida
et al., 2002). The sensitivity was evaluated by determining the
limit of quantification (LOQ), which is defined as the lowest
concentration of the calibration curve that can be measured
with acceptable inter- and intraday precision and accuracy,
assessed respectively by the coefficient of variation (CV) and
the deviation from nominal value (bias) within 20%. The
limit of detection (LOD), defined as the lowest concentration
that can be distinguished from the noise level, was deter-
mined for ESL and its metabolites by analysing plasma
samples with known concentrations, after successive dilutions,
and was established by visual evaluation of the minimum
level at which the analytes can be reliably detected.
Precision and accuracy. Intra- and interday precision and
accuracy were assessed by using QC samples in replicate
at three different concentration levels representative of all
calibration ranges (n = 5). The concentrations tested were 0.4,
4 and 8 μg/mL for ESL and OXC and 0.4, 40 and 80 μg/mL
for each licarbazepine enantiomer. The acceptance criterion,
for precision, was a CV within 15% (or 20% in the LOQ)
and, for accuracy, a bias within 15% (or 20% in the LOQ).
Sample dilution. Dilution effect (1:10) was also investigated
with QC samples at 40 μg/mL for ESL and OXC and at
400 μg/mL for R-LC and S-LC to ensure that plasma samples
exceeding the highest concentration of the calibration range
could be diluted with blank human plasma and accurately
quantified. The precision and accuracy of the diluted QC
samples were determined in both intra- and interday assays
(n = 5).
Recovery. The relative recovery from human plasma was
calculated at 0.4, 4 and 8 μg/mL for ESL and OXC and at 0.4,
40 and 80 μg/mL for licarbazepine enantiomers (n = 5). The
absolute recovery of the internal standard was also evaluated
at the concentration used in sample analysis. The relative
recoveries of the analytes were calculated by comparing the
analyte–internal standard peak height ratios for extracted
samples with the corresponding ratios obtained with non-
extracted standards that represent 100% of recovery. The
absolute recovery of the internal standard was also deter-
mined by calculating the peak height ratio of the internal
standard in extracted samples and non-extracted standards.
Stability. Human plasma stability of ESL and its metabolites
was assessed, at low and high concentration levels, by 24 h at
4°C and 30 days at −30°C to simulate sample handling and
storage time in the freezer before analysis (n = 5). Stability
was assessed by comparing the data of QC samples analyzed
before (reference samples) and after being exposed to the
conditions for stability assessment (stability samples). The
stability sample/reference sample ratios of 85–115% were
accepted as stability criterion.
RESULTS
Chromatographic separation and selectivity
The separation of R-LC, S-LC, OXC, ESL and inter-
nal standard in spiked human plasma was achieved
successfully using the chromatographic conditions
and the solid-phase extraction (SPE) procedure pre-
viously described. Under these analytical conditions
the last-eluting analyte was ESL, with a retention
time of approximately 24 min, and the order of elution
was internal standard, R-LC, S-LC, OXC and ESL,
respectively.
Representative chromatograms of the extracts of
blank and spiked human plasma samples are shown in
Fig. 2. The lack of response in blank human plasma
samples at internal standard and analytes retention
times was demonstrated at 225 nm. Likewise, none
of the possibly co-prescribed drugs or commonly pre-
scribed AED cotherapies tested interfered with the
internal standard or analytes.
Calibration curve
The calibration curves obtained in human plasma
from five calibration standards were linear for ESL and
OXC in the range of 0.4–8 μg/mL and for licarbaze-
pine enantiomers in the range of 0.4–80 μg/mL.
Respectively, the regression equations of calibration
curves were y = 0.0547x + 0.0005 (r2 = 0.993) for ESL,
y = 0.1609x − 0.0061 (r2 = 0.998) for OXC, y = 0.1320x
− 0.0005 (r2 = 0.998) for R-LC and y = 0.1086x − 0.0009
(r2 = 0.998) for S-LC. These results demonstrated
a good linearity (r2 > 0.99) between peak height ratios
and concentrations. The LOQ of the assay was set
at 0.4 μg/mL for all analytes with acceptable precision
and accuracy (Table 1), and the LOD was 0.1 μg/
mL for ESL and 0.04 μg/mL for OXC, R-LC and
S-LC.
Precision and accuracy
Precision and accuracy data for intra and interday
QC plasma samples are presented in Table 1. The
overall intra- and interday CV value was ≤9.25%.
Intra- and interday bias varied between −0.56 and
4.98%. These data indicated that the developed HPLC
method is reproducible and accurate, given that neither
CV nor bias exceeded 15% (or 20% in the LOQ),
in agreement with literature recommendations. The
precision and accuracy of the diluted plasma samples
varied from 0.89 to 2.63% and from −1.96 to 0.38%,
respectively. These results revealed that a 10-fold dilu-
tion with blank human plasma can be rightly applied
if the concentration of a trial sample exceeds the high-
est concentration of the calibration curve.
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Figure 2. Typical chromatograms of extracted human plasma: (A) blank human plasma;
(B) human plasma spiked with internal standard (IS) (concentration = 8 μg/mL), R-
licarbazepine (R-LC), S-licarbazepine (S-LC), oxcarbazepine (OXC) and eslicarbazepine
acetate (ESL) (concentration = 0.4 μg/mL); (C) human plasma spiked with IS (concentration
= 8 μg/mL), R-LC and S-LC (concentration = 20 μg/mL), OXC and ESL (concentration =
2 μg/mL); (D) human plasma spiked with IS (concentration = 8 μg/mL), R-LC and S-LC
(concentration = 80 μg/mL), OXC and ESL (concentration = 8 μg/mL).
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Figure 2. (Continued)
Table 1. Intra- and interday precision (CV, %) and accuracy (bias, %) for the simultaneous determination of eslicarbazepine
acetate (ESL), oxcarbazepine (OXC), S-licarbazepine (S-LC) and R-licarbazepine (R-LC) in human plasma (n = 5)
Assay
Intraday Interday
CNominal
a CV % Bias % CV % Bias % CV % Bias % CV % Bias %
Plasma ESL OXC ESL OXC
0.4 5.52 1.65 6.22 2.53 9.25 1.23 2.63 1.70
4 1.24 0.39 1.65 0.36 2.86 −0.56 1.20 −0.54
8 1.91 3.42 2.16 4.05 0.98 1.97 0.91 3.60
S-LC R-LC S-LC R-LC
0.4 4.10 1.18 3.21 1.02 6.26 0.11 4.22 0.49
40 1.92 0.76 1.85 0.50 2.57 −0.38 2.60 −0.09
80 1.99 4.98 1.98 4.22 0.97 3.29 1.00 3.05
a Nominal concentration (μg/mL); CV, coefficient of variation.
Recovery
The relative drug recoveries from human plasma are
presented in Table 2. The mean relative recoveries,
taking ESL and its metabolites into account, ranged
from 92.36 to 102.85% and showed low CV values. The
absolute recovery of the internal standard was 84.99%,
with a CV of 2.78%. All average recoveries calculated
are high and reproducible, either for analytes or inter-
nal standard.
Table 2. Relative recovery (%) of eslicarbazepine acetate (ESL), oxcarbazepine (OXC),
S-licarbazepine (S-LC) and R-licarbazepine (R-LC) in human plasma
Relative recovery
CNominal
a n Mean (%) CV (%) Mean (%) CV (%)
Plasma ESL OXC
0.4 5 90.10 8.06 85.78 3.27
4 5 100.00 1.87 94.36 1.71
8 5 101.16 1.98 96.93 2.26
15 97.09 6.67 92.36 5.71
S-LC R-LC
0.4 5 97.36 5.38 102.09 4.71
40 5 104.09 1.38 104.99 1.24
80 5 101.57 1.33 101.49 1.30
15 101.01 4.22 102.85 3.25
a Nominal concentration (μg/mL); n, number of samples; CV, coefficient of variation.
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monitoring assays or in bioequivalence studies that
involve the new antiepileptic drug ESL and the already
marketed OXC.
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